![]() ![]() However, experts say Hugin’s actions “aren’t unusual” and the Celgene spokesman Greg Geissman said, “Actions like these are a regular occurrence in many countries outside of the United States where the health authorities assess overall health care spending, including medicines, and impose price actions on the manufacturers.” However, Hugin’s actions as a Celgene executive provided his Democratic opponent and Senate incumbent Robert Menendez with a new attack plan. Trump even invited Pam Holt, a woman from Indiana who claimed she had to refinance her house before she could afford Revlimid, to the White House for his announcement. In May, Trump vowed to fight against high drug prices in the U.S., even though Celgene helped fund Trump’s 2016 campaign-awkward. The head of Patients for Affordable Drugs David Mitchell said, “Celgene is able to continue raising prices because it has managed to keep a generic off-market here and other countries negotiate more aggressively with these drug companies than we do.” FDA Commissioner Scott Gottlieb said Revlimid is one of the top drugs that generic companies request samples from. In less than a year, the price of Revlimid rose from $15,483 in August of 2016 to $18,546 in October of 2017 in the U.S.Īlso under Huglin’s executive power, Ceglene spent a record amount of money in an attempt to defeat new legislation that would have helped generic companies obtain drug samples. The disparity in the price of Revlimid took place during Hugin’s final year as the executive chairman of Celgene Corp. by 20 percent while simultaneously cutting its price by 46 percent in Russia. The documents revealed that in 2017, Hugin raised the price of the cancer drug Revlimid in the U.S. However, new documents could hinder his Senate chances. Former pharmaceutical executive Bob Hugin is running as a Republican for the Senate in New Jersey. ![]()
0 Comments
Leave a Reply. |